GHRP-2 (Pralmorelin)

GHRP-2 (pralmorelin) is a synthetic hexapeptide belonging to the growth hormone-releasing peptide class of GH secretagogues. Developed through systematic modification of the GHRP-1 and GHRP-6 scaffolds, GHRP-2 was designed to optimize GH-releasing potency while improving pharmacokinetic properties. The compound acts as a ghrelin mimetic, binding to and activating the growth hormone secretagogue receptor (GHS-R, also known as the ghrelin receptor) expressed in both the hypothalamus and anterior pituitary somatotroph cells.

GHRP-2 demonstrates 2-3 times greater GH-releasing activity compared to GHRP-6 and GHRP-1 in both rats and humans, representing a significant improvement in potency within the GHRP class. Despite this enhanced activity, GHRP-2 retains the short half-life and limited oral bioavailability characteristic of peptide-based GH secretagogues, necessitating parenteral (injectable) administration for clinical use.

The compound received significant pharmaceutical development attention in the late 1990s and early 2000s. Wyeth (now part of Pfizer) advanced GHRP-2 through Phase II clinical trials in the United States for GH deficiency, while Kaken Pharmaceutical pursued development in Japan for short stature (pituitary dwarfism) under the designation KP-102 LN. However, both development programs appear to have been discontinued—Wyeth’s development ceased without published explanation, and Kaken’s planned 2009 launch never materialized. As of 2026, GHRP-2 is not approved for any indication in any country surveyed by the University of Maryland review.

The mechanism of action involves direct activation of GHS-R on pituitary somatotrophs, increasing the number of cells releasing GH and enhancing pulse amplitude. This mechanism is independent of and complementary to GHRH, which acts through separate GHRH receptors. When GHRP-2 and GHRH analogs (such as sermorelin or CJC-1295) are coadministered, they produce synergistic GH release substantially exceeding either compound alone—a property that drives common combination protocols despite absence of controlled trials validating these regimens.

Beyond GH stimulation, GHRP-2 demonstrates appetite-stimulating effects mediated through ghrelin receptor activation. Clinical studies demonstrated that acute GHRP-2 administration increased ad libitum food intake by 10-34% in a dose-dependent manner in both lean and obese subjects, accompanied by increased hunger ratings. This dual effect—GH release plus appetite stimulation—led to investigation of GHRP-2 for conditions involving both growth impairment and inadequate caloric intake (anorexia nervosa, wasting syndromes).

Mechanism of Action

GHRP-2 operates through the ghrelin receptor (GHS-R) signaling pathway to stimulate GH release and regulate appetite:

Ghrelin Receptor Activation: GHRP-2 binds to and activates GHS-R1a, a G-protein coupled receptor expressed on hypothalamic neurons and pituitary somatotroph cells. Upon ligand binding, the receptor activates Gq proteins, leading to phospholipase C (PLC) activation, inositol trisphosphate (IP₃) production, and intracellular calcium mobilization. This calcium flux triggers immediate GH secretion from stored granules while activating protein kinase C (PKC) and other signaling cascades that enhance GH gene transcription.

Amplification of GH Pulse Amplitude: Unlike GHRH which primarily regulates the amount of GH secreted per pulse, GHRPs like GHRP-2 increase the number of somatotrophs participating in each secretory event, effectively amplifying pulse amplitude. This mechanism is independent of GHRH and does not require intact GHRH signaling, though GHRH receptor presence potentiates GHRP-2’s stimulus.

Somatostatin Suppression: Evidence suggests GHRPs partially work by suppressing somatostatin, the hypothalamic peptide that tonically inhibits GH release. By reducing this inhibitory tone, GHRP-2 permits more robust GH secretion in response to stimulatory signals.

Potency and Efficacy: GHRP-2 demonstrates 2-3 fold greater GH-releasing potency compared to GHRP-6 in both in vitro and in vivo studies, requiring lower doses to achieve equivalent GH elevation. Despite improved potency, GHRP-2 retains relatively short duration of action, with GH levels returning toward baseline within 2-4 hours following single administration.

Synergy with GHRH Analogs: When GHRP-2 is coadministered with GHRH or GHRH analogs (sermorelin, CJC-1295), the combination produces synergistic GH release substantially exceeding the additive effects of either compound alone. This synergy results from complementary mechanisms—GHRH increases GH synthesis and secretion per somatotroph, while GHRP-2 increases the number of cells releasing GH and suppresses somatostatin inhibition. Subject matter experts interviewed for the FDA review consistently cited this synergy as rationale for combination protocols, though no controlled human trials have validated optimal combinations or dosing.

Appetite Stimulation: As a ghrelin mimetic, GHRP-2 activates GHS-R in hypothalamic appetite-regulating centers, stimulating hunger and increasing food intake. The Laferrère studies demonstrated that subcutaneous GHRP-2 infusion increased ad libitum food intake by 10.2% at low dose and 33.5% at high dose compared to placebo, with effects occurring in both lean and obese subjects. Subjects reported greater appetite ratings before meals but similar fullness after eating, suggesting GHRP-2 increases meal initiation drive without affecting satiety signals.

Pharmacokinetics: GHRP-2 exhibits limited oral bioavailability due to peptide structure susceptibility to gastrointestinal degradation, requiring parenteral administration (subcutaneous or intravenous). Following injection, peak GH responses occur within 30-60 minutes, with GH levels declining toward baseline by 2-4 hours. The relatively short duration necessitates multiple daily administrations (typically 2-3 times daily) to maintain elevated GH secretory capacity. Subject matter experts noted that this dosing frequency makes in-office administration impractical, requiring patient self-administration at home.

Physiological Effects

The downstream effects of GH elevation include:

• Body Composition: Increased lean body mass and reduced fat mass through enhanced protein synthesis and lipolysis
• Growth: Increased height velocity in children with growth impairment (demonstrated in clinical trials)
• Metabolic Effects: GH antagonizes insulin, potentially affecting glucose metabolism; IGF-I production mediates anabolic effects
• Appetite and Weight: Direct appetite stimulation may increase food intake and body weight independent of GH effects
• Bone Metabolism: Enhanced bone turnover through GH/IGF-I axis
• Recovery and Healing: Potential improvements in tissue repair and wound healing

Comprehensive Systematic Review

University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI), 2021 – Growth hormone-releasing peptide-2: Summary Report for FDA 503B Bulks List Evaluation

Comprehensive scoping review examining clinical use of GHRP-2 to assist FDA in evaluating inclusion on the 503B Bulks List for compounding.

Systematic Literature Review Methodology:

• Comprehensive search of Ovid MEDLINE and Embase databases through November 30, 2019
• PRISMA-compliant systematic review process
• Inclusion criteria: Studies using GHRP-2 in nominated dosage forms/routes to diagnose, prevent, or treat any condition
• Two independent reviewers screened 267 titles/abstracts after deduplication
• 36 full-text articles reviewed

**Results:**

• Total studies included: 4
• Reasons for exclusions: Wrong study design (13 studies); GHRP-2 used as brand/proprietary product (8); wrong indication (6); wrong dosage form/route (4); GHRP-2 not used clinically (1)
• Total patients: 46 across 4 studies
• Study countries: Australia, Belgium, Japan, Russia, United States
• Publication period: 1995-2015

**Indications Studied:**

• Short stature (31 patients): Idiopathic or due to GH deficiency; intranasal doses 10-45 µg/kg/day or IV 1 µg/kg; duration 1 dose to 24 months
• Anorexia nervosa (1 patient): Intranasal 100-700 µg/day for 10 months
• Wasting syndrome (14 patients): IV 1 µg/kg to 1 µg/kg/hour for 5 days

Key Finding: GHRP-2 is not available as an FDA-approved product in any dosage form or route. GHRP-2 is not available in any of the 13 foreign national registries searched (Canada, EU, UK, Ireland, Belgium, Latvia, Australia, New Zealand, Saudi Arabia, Abu Dhabi, Hong Kong, Namibia).

Subject Matter Expert Interviews (N=4 SMEs):

• Clinical context: SMEs confirmed limited use of GHRP-2 as monotherapy; more commonly used in combination with GHRP-6 and/or sermorelin
• Primary applications: “Lifestyle medications” for patients seeking improvements in physical appearance (skin, hair, body composition) rather than medical necessity
• Typical patients: Often prescribed after testosterone replacement therapy in hypogonadal men who desire additional body composition improvements
• Dosing practices: Typically 100-500 µg/day subcutaneously, up to 1,000 µg/day when combined with sermorelin; requires multiple daily doses due to circadian GH rhythm
• Combination rationale: SMEs cited synergistic effects when combining secretagogues acting through different receptors (GHRP-2 on GHS-R, sermorelin on GHRH-R), though acknowledged “limited literature” supporting specific combinations or doses
• Monitoring: IGF-I levels used as surrogate for GH (due to GH’s 2-3 minute half-life); treatment considered if baseline IGF-I <150 ng/mL; physical appearance changes also tracked
• Safety perspective: SMEs stated GH secretagogues are “much safer than growth hormones because they’re stimulating the natural pathway” rather than shutting down endogenous production
• Evidence gaps: “Limited literature” on optimal dosing, combinations, and long-term outcomes; most studies examine GH pathway activation rather than downstream functional effects

**Survey Results:**

• Professional medical associations: Zero respondents
• Key finding: Complete absence of survey responses suggests extremely limited adoption in mainstream medical practice

**Conclusion:** “In the 4 studies included from the literature review, GHRP2 was used for treatment of short stature, and to stimulate appetite and increase body weight and muscle mass in patients with anorexia nervosa or critical illness… Several SMEs stated that there was limited outcomes-based human research on the clinical use of GH and GH secretagogues, making it difficult to know the ideal combination and dose of medication to use, and the effects of long-term use.”

Significance: This FDA-commissioned review demonstrates a profound evidence gap for GHRP-2—only 4 small studies examining narrow indications (short stature, eating disorders, critical illness), zero studies examining the body composition and anti-aging applications driving current off-label use, and complete absence of evidence for combination protocols despite widespread practice.

Appetite Stimulation Studies

Laferrère B et al., 2005 – Growth Hormone Releasing Peptide-2 (GHRP-2), Like Ghrelin, Increases Food Intake in Healthy Men

Design: Randomized, double-blind, placebo-controlled crossover study in 7 lean healthy men examining acute effects of GHRP-2 on appetite and food intake.

Study Protocol:

• Participants received subcutaneous infusion of either GHRP-2 (1 µg/kg/hr) or saline placebo for 270 minutes
• Fixed breakfast (320 kcal) at 120 minutes
• Ad libitum buffet lunch at 240 minutes with instruction to eat as much as desired
• Hunger and fullness ratings on visual analog scales
• Serial blood sampling for GH and other hormones

*Results:*

• Food intake: GHRP-2 significantly increased ad libitum food intake compared to saline (p<0.01)
• GH levels: Serum GH rose significantly during GHRP-2 infusion compared to saline (p<0.01)
• Appetite ratings: Increased hunger with GHRP-2 administration
• Safety: Well-tolerated without adverse effects

Follow-up Study: Obesity and Dose-Response

Design: Randomized, double-blind, placebo-controlled study in 19 subjects (10 lean, 9 obese) examining dose-dependent effects of GHRP-2.

Results:

• Low dose (0.1 µg/kg/hr): Increased food intake by 10.2±3.9% vs. placebo (p=0.011)
• High dose (1 µg/kg/hr): Increased food intake by 33.5±5.8% vs. placebo (p=0.000)
• Obesity status: Did not influence GHRP-2’s effect on food intake—both lean and obese subjects responded similarly
• GH response: Dose-dependent increases in serum GH in all subjects
• Appetite ratings: All subjects reported greater appetite before meals but similar fullness after eating with high-dose GHRP-2

Significance: These studies establish that GHRP-2’s appetite-stimulating effects occur acutely in humans, are dose-dependent, and persist in obesity. This dual action (GH release + appetite stimulation) distinguishes GHRP-2 from GHRH analogs and suggests potential applications in conditions requiring both anabolic support and increased caloric intake.

Combination Therapy Study

Sigalos JT et al., 2017 – Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels

Design: Retrospective review of 105 hypogonadal men on testosterone therapy who were prescribed GHRP-2 100 µg / GHRP-6 100 µg / sermorelin 100 µg subcutaneously three times daily.

Study Population:

• 14 patients met inclusion criteria: adherence to dosing regimen and baseline IGF-I <200 ng/mL
• All patients on concurrent testosterone replacement therapy
• Goal: Increase lean body mass and promote fat loss

*Results:*

• IGF-I elevation: Combination therapy produced significant increases in IGF-I levels (p<0.05)
• Interpretation: Demonstrates that triple-combination GH secretagogue therapy can elevate IGF-I biomarker in hypogonadal men

*Limitations:*

• Small sample size (N=14) from highly selected population
• No placebo control group
• Retrospective design with selection bias (only adherent patients with specific baseline characteristics included)
• No functional outcomes measured (body composition, strength, quality of life not assessed)
• Cannot determine contribution of individual components vs. combination effect
• Concurrent testosterone therapy confounds interpretation

Significance: This represents the only published study examining the GHRP-2 / GHRP-6 / sermorelin combination frequently mentioned by SMEs in the University of Maryland review. While it demonstrates biomarker elevation (IGF-I), the study provides no evidence for functional benefits and suffers from significant methodological limitations.

Broader GH Secretagogue Context

Sigalos JT & Pastuszak AW, 2018 – The Safety and Efficacy of Growth Hormone Secretagogues

Systematic review of GH secretagogues providing context for GHRP-2 within the broader class.

Key Points:

• GH secretagogues preserve pulsatile GH release subject to negative feedback, theoretically avoiding supratherapeutic levels associated with recombinant GH
• GHRP-2 demonstrates 2-3× greater potency than GHRP-6 in stimulating GH release
• Combination of GHRPs with GHRH analogs produces synergistic GH elevation
• Evidence base focuses predominantly on biomarker changes (GH, IGF-I elevation) rather than functional outcomes
• Long-term safety data insufficient across the GH secretagogue class
• Glucose metabolism concerns: GH elevation can increase insulin resistance, elevating blood glucose and HbA1c

Research Status

As of January 2026, GHRP-2 (pralmorelin) is not FDA-approved for any medical indication and is not approved in any of the 13 countries/regions surveyed by the University of Maryland review. Pharmaceutical development by both Wyeth (US) and Kaken (Japan) was discontinued without published explanation, suggesting either commercial challenges, insufficient efficacy in clinical trials, or safety concerns that halted advancement.

The FDA-commissioned systematic review identified only 4 human clinical trials meeting inclusion criteria—examining short stature, anorexia nervosa, and wasting syndrome—with zero trials evaluating body composition or anti-aging applications that currently drive off-label use. The stark finding of zero survey respondents from professional medical associations suggests GHRP-2 use is largely confined to “lifestyle medicine” practices outside mainstream medical specialties.

Subject matter expert interviews revealed that GHRP-2 is rarely used as monotherapy, more commonly prescribed in combination with GHRP-6 and/or sermorelin based on theoretical synergy rather than clinical trial evidence. SMEs acknowledged “limited literature” on optimal combinations, dosing, and long-term outcomes, with prescribing decisions based on pharmacological reasoning, anecdotal experience, and patient demand rather than evidence-based guidelines.

Potential Research Applications

Growth Hormone Deficiency: GHRP-2 was investigated for GH deficiency in pharmaceutical development programs that were subsequently discontinued. While preclinical and early clinical data demonstrated GH-releasing activity, progression to approval suggests either inadequate efficacy, safety concerns, or commercial challenges. For documented GH deficiency, FDA-approved recombinant GH remains the evidence-based standard of care.

Short Stature in Children: The University of Maryland review identified studies using intranasal GHRP-2 (10-45 µg/kg/day) for 6-24 months in children with idiopathic short stature or GH insufficiency. Results suggested “modest” increases in growth velocity, but discontinuation of pharmaceutical development by Kaken indicates outcomes were insufficient for commercial viability or regulatory approval.

Appetite Stimulation and Wasting: GHRP-2’s dual effects—GH stimulation and appetite increase—created interest for conditions involving both growth impairment and inadequate caloric intake. Studies in anorexia nervosa (N=1) and critical illness wasting (N=14) showed some promise, but extremely small sample sizes and lack of follow-up research suggest limited enthusiasm for these applications.

Body Composition Optimization: SME interviews revealed this as the primary current application—prescribed to patients (often already on testosterone therapy) seeking improvements in lean mass and fat loss. However, the University of Maryland review found zero clinical trials examining GHRP-2 for body composition in healthy adults or as enhancement therapy. The single study in hypogonadal men showed IGF-I elevation but measured no functional outcomes.

Combination Protocols: SME interviews consistently cited combination therapy (GHRP-2 + GHRP-6 + sermorelin) as “trending” based on synergistic GH release mechanisms. The Sigalos 2017 study examined this specific combination in 14 patients, demonstrating IGF-I elevation but no functional benefits. No controlled trials have systematically evaluated optimal combinations, doses, or schedules for any indication.

Safety Profile Summary

The University of Maryland review identified limited safety data:

Short-term tolerance (4 studies, N=46):

• Well-tolerated in short stature studies (duration: single dose to 24 months)
• Well-tolerated in appetite stimulation studies (single infusions)
• Well-tolerated in wasting syndrome study (5-day infusion)

**Known effects:**

• Appetite stimulation and increased food intake (dose-dependent, 10-34% increases)
• GH elevation with associated metabolic effects
• Potential effects on glucose metabolism (theoretical concern with all GH-elevating interventions)

**Critical Safety Gaps:**

• No long-term safety data: Maximum exposure 24 months in small pediatric sample; chronic use safety completely unknown
• Discontinued development: Pharmaceutical companies discontinued GHRP-2 programs without published explanation, raising questions about unpublished safety or efficacy concerns
• IGF-I and cancer risk: Theoretical concerns about sustained IGF-I elevation and malignancy risk unaddressed by available studies
• Glucose metabolism: GH antagonizes insulin; long-term effects on glucose tolerance, diabetes risk unknown
• No safety studies for lifestyle use: All clinical trials examined medical conditions (GH deficiency, eating disorders, critical illness); safety in healthy adults seeking enhancement unstudied

Important Considerations

Profound Evidence Gap for Current Use: The University of Maryland review reveals perhaps the starkest evidence-practice disconnect in the peptide field. Zero of 4 included studies examined body composition or anti-aging applications, yet SMEs describe these as primary current uses. All prescribing for these indications occurs without supporting clinical trial evidence.

Discontinued Pharmaceutical Development: Both Wyeth and Kaken advanced GHRP-2 through Phase II trials but discontinued development without published explanation. This strongly suggests that either efficacy was insufficient, safety concerns emerged, or commercial viability was inadequate—important context rarely discussed in “lifestyle medicine” promotion of GHRP-2.

“Lifestyle Medicine” Context: SME interviews revealed GHRP-2 is prescribed primarily as “patient demand-based medicine” for physical appearance improvements rather than medical necessity. Prescribing occurs in specialized practices (often urology, naturopathy, anti-aging clinics) rather than mainstream endocrinology, explaining zero survey responses from professional medical associations.

Combination Protocols Lack Evidence: Despite widespread use of GHRP-2 / GHRP-6 / sermorelin combinations and SME enthusiasm for “synergistic” effects, only one small retrospective study examined this combination—finding IGF-I elevation but no functional outcomes. All combination rationale derives from pharmacological theory, not clinical efficacy trials.

Rarely Used as Monotherapy: SMEs indicated GHRP-2 is more commonly prescribed in combination with other GH secretagogues than as single-agent therapy. This practice complicates attribution of effects or adverse events to specific components and increases complexity, cost, and injection burden.

Dosing Based on Anecdote: SMEs acknowledged “limited literature” on optimal dosing, stating patients are started on low doses and titrated based on tolerance and desired outcomes rather than evidence-based protocols. Typical dosing (100-500 µg/day subcutaneously, 2-3 times daily) derives from clinical experience rather than dose-finding trials.

Multiple Daily Injections Required: GHRP-2’s short duration necessitates 2-3 daily subcutaneous injections to maintain GH secretory capacity. This creates substantial compliance burden compared to weekly alternatives (CJC-1295 with DAC) and makes in-office administration impractical, requiring patient self-administration.

Appetite Stimulation May Be Undesired: For applications focused on fat loss, GHRP-2’s appetite-stimulating effects (10-34% increases in food intake) may be counterproductive. Other GH secretagogues without appetite effects (ipamorelin, CJC-1295, sermorelin alone) may be preferable for body composition applications.

Product Quality Variability: As an unapproved compound available only through research suppliers and compounding pharmacies, GHRP-2 product quality, purity, and dosage accuracy vary substantially. The University of Maryland review noted that even 503B outsourcing facilities face challenges with GHRP-2 production. No regulatory oversight ensures product consistency or safety.

No Approval Anywhere: Unlike some peptides approved in select countries, GHRP-2 is not approved in any of 13 countries/regions surveyed—United States, Canada, EU, UK, Ireland, Belgium, Latvia, Australia, New Zealand, Saudi Arabia, Abu Dhabi, Hong Kong, or Namibia. This global absence of approval is notable and suggestive of fundamental limitations.

Regulatory and Legal Status: GHRP-2 is not FDA-approved for any indication and is prohibited by WADA for competitive athletes. Use outside approved clinical trials may carry legal and professional consequences. Prescribing occurs in regulatory gray zones without established clinical guidelines.

Alternative Approaches Exist: For documented GH deficiency, FDA-approved recombinant GH provides evidence-based treatment.² For enhancement applications, no peptide-based secretagogue has sufficient evidence to recommend over established interventions (resistance training, adequate protein, sleep optimization) with proven efficacy and safety.

1. University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI). Growth hormone-releasing peptide-2: Summary Report prepared for Food and Drug Administration. January 2021.
2. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues.
3. Laferrère B, Abraham C, Russell CD, Bowers CY. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. Journal of Clinical Endocrinology & Metabolism. 2005;90(2):611-614.
4. Laferrère B, Hart AB, Bowers CY. Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake. Obesity. 2006;14(6):1056-1063.
5. Sigalos JT, Pastuszak AW, Allison A, et al. Growth hormone secretagogue treatment in hypogonadal men raises serum insulin-like growth factor-1 levels. American Journal of Men’s Health. 2017;11(6):1752-1758.

References

This content is for educational and research purposes only and does not constitute medical advice.

GHRP-2 is not FDA-approved for any medical indication and is not approved in any country surveyed by comprehensive regulatory review.

A 2021 FDA-commissioned systematic review identified only 4 small clinical trials examining narrow indications (short stature, eating disorders, critical illness), with zero trials evaluating body composition or anti-aging applications that currently drive off-label use.

Pharmaceutical development programs by major companies were discontinued without published explanation.

Current evidence does not support efficacy for applications driving widespread use.

All products are intended strictly for laboratory research and development purposes only.